• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

What We're Reading: Awaiting Alzheimer's Drug Clinical Trial Results

Article

What we’re reading, October 13, 2016: researchers, Alzheimer’s patients, and their families anxiously await the results of a clinical trial that could help slow the disease’s progress; many breast cancers detected by mammograms are overtreated even though they likely would not be fatal on their own; stock prices fall for Humana and Cigna as CMS says a minority of their patients are in plans rated 4 stars or higher.

Clinical trial results for a drug to treat Alzheimer’s disease should be released in the coming month, leaving researchers, patients, and their families cautiously optimistic in the meantime. Solanezumab, which is being tested by Eli Lilly, is an injected antibody that could potentially clear the plaques that accumulate in the brains of patients with Alzheimer’s disease. However, researchers worry that the drug could join the 99% of experimental treatments for the disease that have failed in clinical trials, which would further crush hope for those affected.

More than half of women diagnosed with breast cancer after a mammogram received treatment they didn’t actually need, subjecting them to unnecessary anxiety, treatments, and costs. A study in the New England Journal of Medicine found that most abnormalities detected by mammograms would likely never become deadly tumors if left untreated. Researchers now say that the mammogram's status as a life-saving prevention measure may be overblown, and more effective treatments, not screening measures, are the reason breast cancer survival rates have improved.

Humana and Cigna both suffered drops in stock prices after CMS released discouraging star ratings. The percentage of Medicare Advantage patients in Humana plans that rated 4 stars or higher fell to 37%, down from 78% last year; only 20% of Cigna’s patients are in 4-star or higher plans. In contrast, 91% of Aetna members are in 4-star plans.

Related Videos
Video 1 - "Diagnosing and Understanding the Pathogenesis of Bronchiectasis"
Video 4 - "Challenges in Autoantibody Screening for Type 1 Diabetes"
Jeff Stark, MD, vice president, head of medical immunology, UCB
Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"
Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"
Video 6 - "Community Partnership: Increasing Public Awareness of CVD"
Video 6 - "Community Partnership: Increasing Public Awareness of CVD"
Screenshot of Raajit Rampal, MD, PhD
 Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.